



Biomarkers For Neurological Diseases

Proven Track-Record

Neurotoxicity



tTau

BACE-1

A β -40

A β -42

pTau231

α -Synuclein TDP43

Neuroinflammation



STREM-2


GFAP

YKL-40

Progranulin

CCL2

IL-1 α , IL-1 β , IL-6



Neuronal Damage



pNF-H

NFL

Neurogranin

Blood Brain Barrier Integrity



Claudin-5

AQ-4

ICAM-1

ZO-1

VCAM-1

Occludin

Non-exhaustive list of examples: PD: Parkinson's Disease / AD: Alzheimer's Disease
HD: Huntington's Disease / MSA: Multiple System Atrophy / DLB: Dementia with Lewy Bodies
MS: Multiple Sclerosis / ALS: Amyotrophic Lateral Sclerosis / PSP: Progressive Supranuclear Palsy



Different Needs. Different Solutions!

Technologies & Capabilities

Therapeutic Modalities

- Small Molecules
- Biologics
- Vaccines
- Cell & Gene Therapies

Preclinical & Clinical Studies (regulated and non-regulated)

- Mice
- Non-Human Primates
- Humans (Phase 1 to 4)

Biomarker Analysis



MSD



Luminex®



Ella™



Simoa™ HD-X

Development Phase

- Method development
- Method validation
- Preclinical studies
- Clinical studies

Biological Matrices

- Serum
- Plasma
- CSF
- Cell & Tissue lysates



Active Biomarkers
Lyon – France
active-biomarkers.com



KCAS
Kansas City – USA
kcasbio.com



Flow Metric
Philadelphia - USA
Milan – Italy
flowmetric.com